By Fineline Cube 
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South Korea-headquartered Alvogen Korea Co., Ltd. regarding its HanSiZhuang (serplulimab) drug.
Deal Details
Under the agreement, Alvogen gains exclusive commercialization rights to HanSiZhuang in South Korea. The drug is indicated for non-squamous non-small cell lung cancer (nsqNSCLC), extensive stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), metastatic colorectal cancer (mCRC), and gastric cancer (GC).
Financial Terms
Henlius will receive USD 5 million as an upfront payment. In addition, the company is eligible for up to USD 9.5 million in regulatory milestone payments and up to USD 97.5 million in commercial milestone payments. Alvogen will also pay tiered royalties of 18% to 25% of annual net sales.-Fineline Info & Tech